Targeting the transferrin receptor to transport antisense oligonucleotides across the mammalian blood-brain barrier.

Autor: Barker SJ; Denali Therapeutics Inc., South San Francisco, CA, USA., Thayer MB; Denali Therapeutics Inc., South San Francisco, CA, USA., Kim C; Denali Therapeutics Inc., South San Francisco, CA, USA., Tatarakis D; Denali Therapeutics Inc., South San Francisco, CA, USA., Simon MJ; Denali Therapeutics Inc., South San Francisco, CA, USA., Dial R; Denali Therapeutics Inc., South San Francisco, CA, USA., Nilewski L; Denali Therapeutics Inc., South San Francisco, CA, USA., Wells RC; Denali Therapeutics Inc., South San Francisco, CA, USA., Zhou Y; Denali Therapeutics Inc., South San Francisco, CA, USA., Afetian M; Ionis Pharmaceuticals, Carlsbad, CA, USA., Akkapeddi P; Denali Therapeutics Inc., South San Francisco, CA, USA., Chappell A; Ionis Pharmaceuticals, Carlsbad, CA, USA., Chew KS; Denali Therapeutics Inc., South San Francisco, CA, USA., Chow J; Denali Therapeutics Inc., South San Francisco, CA, USA., Clemens A; Denali Therapeutics Inc., South San Francisco, CA, USA., Discenza CB; Denali Therapeutics Inc., South San Francisco, CA, USA., Dugas JC; Denali Therapeutics Inc., South San Francisco, CA, USA., Dwyer C; Ionis Pharmaceuticals, Carlsbad, CA, USA., Earr T; Denali Therapeutics Inc., South San Francisco, CA, USA., Ha C; Denali Therapeutics Inc., South San Francisco, CA, USA., Ho YS; Denali Therapeutics Inc., South San Francisco, CA, USA., Huynh D; Denali Therapeutics Inc., South San Francisco, CA, USA., Lozano EI; Denali Therapeutics Inc., South San Francisco, CA, USA., Jayaraman S; Denali Therapeutics Inc., South San Francisco, CA, USA., Kwan W; Denali Therapeutics Inc., South San Francisco, CA, USA., Mahon C; Denali Therapeutics Inc., South San Francisco, CA, USA., Pizzo M; Denali Therapeutics Inc., South San Francisco, CA, USA., Robles-Colmenares Y; Denali Therapeutics Inc., South San Francisco, CA, USA., Roche E; Denali Therapeutics Inc., South San Francisco, CA, USA., Sanders L; Denali Therapeutics Inc., South San Francisco, CA, USA., Stergioulis A; Denali Therapeutics Inc., South San Francisco, CA, USA., Tong R; Denali Therapeutics Inc., South San Francisco, CA, USA., Tran H; Denali Therapeutics Inc., South San Francisco, CA, USA., Zuchero Y; Denali Therapeutics Inc., South San Francisco, CA, USA., Estrada AA; Denali Therapeutics Inc., South San Francisco, CA, USA., Gadkar K; Denali Therapeutics Inc., South San Francisco, CA, USA., Koth CMM; Denali Therapeutics Inc., South San Francisco, CA, USA., Sanchez PE; Denali Therapeutics Inc., South San Francisco, CA, USA., Thorne RG; Denali Therapeutics Inc., South San Francisco, CA, USA., Watts RJ; Denali Therapeutics Inc., South San Francisco, CA, USA., Sandmann T; Denali Therapeutics Inc., South San Francisco, CA, USA., Kane LA; Denali Therapeutics Inc., South San Francisco, CA, USA., Rigo F; Ionis Pharmaceuticals, Carlsbad, CA, USA., Dennis MS; Denali Therapeutics Inc., South San Francisco, CA, USA., Lewcock JW; Denali Therapeutics Inc., South San Francisco, CA, USA., DeVos SL; Denali Therapeutics Inc., South San Francisco, CA, USA.

Publikováno v: Science translational medicine [Sci Transl Med] 2024 Aug 14; Vol. 16 (760), pp. eadi2245. Date of Electronic Publication: 2024 Aug 14.